Stock Market News, Outlooks, and Top Picks, Cappuccino Finance

Cappuccino Finance

Stock Market News, Outlooks, and Top Picks

Cappuccino Finance, provides Financial vignettes for your cappuccino break!

Fun & informational articles to read in 10 min or less.

Equity Bottom-Up

<ul><li>It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildly</li><li>Healthcare companies provide essential services regardless of economic conditions.</li><li>The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!</li></ul>

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildlyHealthcare companies provide essential services regardless of economic conditions.The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!

Dividend HealthCare Stocks Screener – Jan 2022

Actionable Insights, Assured Alpha, ANTYA Investments

ANTYA Investments

Actionable Insights, Assured Alpha

Investing That Empowers You

ANTYA Investments Inc., regulated by the Ontario Securities Commission, is registered to provide wealth management services in Canada. ANTYA manages institutional, and high net-worth client portfolios on a discretionary basis. Our investment philosophy embraces a Core-Satellite approach.  The core of the portfolio is chosen from a group of fifteen asset classes. A few stock specific asymmetrical investment opportunities comprise the satellite segment. ANTYA invests only in global, large capitalization, and investment grade companies.  

Event-Driven

<p>A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in the pharmaceutical space within days. In this note, we discuss <a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb's Co (BMY US)</a> acquisition of <a href="https://www.smartkarma.com/entities/7410" target="_blank" data-smartkarma-citation="entities:7410:1">Celgene Corp (CELG US)</a> and  outline our view that investors should go long BMY.</p>

A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in the pharmaceutical space within days. In this note, we discuss Bristol Myers Squibb's Co (BMY US) acquisition of Celgene Corp (CELG US) and  outline our view that investors should go long BMY.

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Abbvie Inc (ABBV US)

Dividend HealthCare Stocks Screener – Jan 2022

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to...

Cappuccino Finance

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...

ANTYA Investments